Advertisement
U.S. markets closed

Imunon, Inc. (IMNN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.5890+0.0234 (+4.14%)
At close: 04:00PM EST
0.5900 +0.00 (+0.17%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close0.5656
Open0.5700
Bid0.5890 x 1100
Ask0.5900 x 900
Day's Range0.5603 - 0.5890
52 Week Range0.4800 - 1.6300
Volume37,344
Avg. Volume58,736
Market Cap5.536M
Beta (5Y Monthly)1.69
PE Ratio (TTM)N/A
EPS (TTM)-3.2500
Earnings DateMar 28, 2024 - Apr 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IMNN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Imunon, Inc.
    Daily – Vickers Top Insider Picks for 02/22/2024The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine

    Data Show Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccine Modality LAWRENCEVILLE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that an article titled “Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functional polymer” by Subeena Sood, Majed M. Matar, et

  • GlobeNewswire

    IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Accomplished pharmaceutical and biotechnology executive to lead IMUNON’s clinical programs in ovarian cancer and infectious diseases LAWRENCEVILLE, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Sebastien Hazard, M.D. as Chief Medical Officer, effective December 11, 2023. Dr. Hazard brings to IMUNON a strong backgrou

  • Insider Monkey

    Imunon, Inc. (NASDAQ:IMNN) Q3 2023 Earnings Call Transcript

    Imunon, Inc. (NASDAQ:IMNN) Q3 2023 Earnings Call Transcript November 17, 2023 Operator: Good morning. My name is Alan, and I will be your operator today. At this time I would like to welcome you to Imunon’s Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] I would like now to turn the call over to […]